

# MedStar Health, Inc.

## POLICY AND PROCEDURE MANUAL

Policy Number: PA.096.MH  
Last Review Date: 02/14/2020  
Effective Date: 04/01/2020

### PA.096.MH – Esophagogastroduodenoscopy

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar CareFirst PPO

MedStar Health considers an **Esophagogastroduodenoscopy (EGD)** medically necessary for the following indications:

For a repeat endoscopy within 12 months, one of the following must be true:

1. Patient has new or recurrent alarm symptoms:
  - Dysphagia or odynophagia
  - bleeding
  - persistent vomiting of unknown cause

**Or**

2. Patient has one of the following esophageal diagnoses and any one of the following conditions:
  - a. Barrett's Esophagus (BE) with or without esophageal dysplasia:
    - After a diagnosis of BE, one repeat endoscopy may be performed in six months. Following that, surveillance should be at three to five year intervals.
    - After biopsy confirmed low grade dysplasia (LGD), one repeat EGD may be performed in six months. Following that, annual surveillance EGD with biopsies is recommended.
    - After biopsy confirmed high grade esophageal dysplasia (HGD) in patients not immediately treated, unfit or unwilling to undergo ablative or operative therapy, endoscopic surveillance with biopsies may be considered every three months for the first year, every six months the following year, and annually thereafter.

**Or**

- b. Previous endoscopy showed severe erosive esophagitis. Patient has documented compliance with eight weeks of a Proton Pump Inhibitors (PPI) therapy. One repeat endoscopy is to assess extent of healing of esophagitis and determine if dysplasia is present which may have been masked by the acute inflammation.

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
Last Review Date: 02/14/2020  
Effective Date: 04/01/2020

- i. In absence of BE, repeat endoscopy after this initial follow-up examination is not indicated

Or

- c. Patient has known esophageal stricture and symptoms suggest recurrence in need of dilation.

Or

- d. Patient has esophageal cancer:
  - Endoscopic evaluation, including endoscopic ultrasound or endoscopic fine needle aspiration (FNA) can be used for staging a newly diagnosed esophageal cancer, or restaging after neoadjuvant chemoradiation.
  - Endoscopic provision of curative or palliative treatment of esophageal cancer or high grade dysplasia.

Or

- e. Patient has esophageal varices.

Or

3. Patient has one of the following gastric or ulcer diagnoses and one of the following conditions:

- a. H. pylori associated MALT lymphoma, treated with antibiotics, for purposes of re-biopsy to evaluate response, every one to three months until a histologic complete response and then every six months for two years.

Or

- b. Selected esophageal, gastric, or stomal ulcers if patient remains symptomatic despite an appropriate course of medical therapy or patient with gastric ulcer without clear etiology who did not undergo biopsy at the index EGD unless healing has been demonstrated.

Or

- c. One repeat EGD at six months for follow-up in patients with FAP only in cases where gastric adenomas or adenomas of the duodenum were demonstrated.

Or

4. One repeat EGD/ endoscopic ultrasound can be performed by a different provider for purposes of obtaining a second opinion.

**Repeat endoscopic ultrasounds for any medical reason other than the indications listed in the policy will be evaluated on a case by case basis.**

### Limitations

1. Only one EGD will be covered in a 12 month period without prior authorization. Repeat EGD within 12 months requires prior authorization.
2. Repeat EGD is not indicated and not covered for any of the following conditions:
  - a. Surveillance of malignancy in members with gastric atrophy, pernicious anemia, treated achalasia, or prior gastric operation

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
Last Review Date: 02/14/2020  
Effective Date: 04/01/2020

- b. Surveillance of healed benign disease such as esophagitis, gastric or duodenal ulcer
- c. Surveillance during chronic repeated dilations of benign strictures unless there is a change in status

### Background

Endoscopic examinations may be used to evaluate symptoms, identify anatomic abnormalities, to obtain biopsies, or are employed for therapeutic reasons. Most often the procedure is performed by a fiberoptic endoscope (including video endoscopy), a flexible tube containing light transmitting glass fibers that return a magnified image directly or by video.

An Esophagogastroduodenoscopy (EGD) is an endoscopic test that examines the lining of the esophagus, stomach and first part of the small intestine for the diagnosis and/or treatment of a variety of GI diseases.

### Codes:

CPT Codes	
Code	Description
43191	Esophagoscopy, rigid, transoral; diagnostic, including collection of specimen(s) by brushing or washing when performed (separate procedure)
43192	with directed submucosal injection (s), any substance
43193	with biopsy, single or multiple
43194	with removal of foreign body
43195	with balloon dilation (less than 30 mm diameter)
43196	with insertion of guide wire followed by dilation over guide wire
43197	Esophagoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing when performed (separate procedure)
43198	with biopsy, single or multiple
43200	Esophagoscopy, flexible, transoral, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
43201	with directed submucosal injection (s), any substance
43202	with biopsy, single or multiple`
43204	with injection sclerosis of esophageal varices

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
 Last Review Date: 02/14/2020  
 Effective Date: 04/01/2020

43205	with band ligation of esophageal varices
43206	with optical endomicroscopy
43215	with removal of foreign body
43216	with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery
43217	with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
43211	with endoscopic mucosal resection
43212	with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)
43213	with dilation of esophagus, by balloon or dilator, retrograde (includes fluoroscopic guidance, when performed)
43214	with dilation of esophagus, with balloon (30 mm diameter or larger) (includes fluoroscopic guidance, when performed)
43226	with insertion of guide wire followed by passage of dilator(s) over guide wire
43231	with endoscopic ultrasound examination
43232	with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s)
43235	Esophagogastroduodenoscopy, flexible, transoral: diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
43236	with directed submucosal injection(s), any substance
43237	with endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures
43238	with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration /biopsy(s), esophagus (includes endoscopic ultrasound examination limited to the esophagus, stomach, or duodenum, and adjacent structures)
43239	with biopsy, single or multiple
43241	with insertion of intraluminal tube or catheter
43242	with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
 Last Review Date: 02/14/2020  
 Effective Date: 04/01/2020

	or a surgically altered stomach where the jejunum is examined distal to the anastomosis)
43243	with injection sclerosis of esophageal/gastric varices
43248	with insertion of guide wire followed by dilation of esophagus over guide wire
43249	with balloon dilation of esophagus (less than 30 mm diameter)
*43233	with dilation of esophagus with balloon (less than 30 mm diameter) (includes fluoroscopic guidance when performed)
43250	with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery
43251	with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
43252	with optical endomicroscopy
43253	with transendoscopic ultrasound-guided transmural injection of diagnostic or therapeutic substance(s) (e.g. anesthetic, neurolytic agent) or fiducial markers(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis)
43254	with endoscopic mucosal resection
43266	with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)
43259	with endoscopic ultrasound examination, including the esophagus, stomach, and either the duodenum and/or jejunum as appropriate
43270	Esophagogastroduodenoscopy, flexible, transoral; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre- and post-dilation and guide wire passage, when performed)
76975	Gastrointestinal endoscopic ultrasound

### References

1. American Society of Gastrointestinal Endoscopy (ASGE). Standards of Practice Committee. The role of endoscopy in the assessment and treatment of esophageal cancer. *Gastrointest Endosc.* 2013 Mar;77(3):328-344. doi: 10.1016/j.gie.2012.10.001 [https://www.giejournal.org/article/S0016-5107\(12\)02765-4/pdf](https://www.giejournal.org/article/S0016-5107(12)02765-4/pdf)

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
Last Review Date: 02/14/2020  
Effective Date: 04/01/2020

2. American Society of Gastrointestinal Endoscopy (ASGE). Standards of Practice Committee The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus, *Gastrointest Endosc* 2012 Dec; 76(6):1087-1094. doi: 10.1016/j.gie.2012.08.004. <https://www.ncbi.nlm.nih.gov/pubmed/23164510>
3. American Society for Gastrointestinal Endoscopy (ASGE). Guideline- the Role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. *Gastrointestinal Endoscopy*. 2006; 63(4): 570-580., doi:10.1016/j.gie.2006.02.004. [https://www.giejournal.org/article/S0016-5107\(06\)00233-1/pdf](https://www.giejournal.org/article/S0016-5107(06)00233-1/pdf)
4. Centers for Medicare and Medicaid Services (CMS). Local Coverage Article: Billing and Coding: Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic) No. A57414. Revision Effective Date: 10/01/2019 <https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=57414&ver=6&Date=&DocID=A57414&bc=ggAAAAgAAAA&>
5. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD). LCD No. L35350 – Upper Gastrointestinal Endoscopy (Diagnostic and Therapeutic). Revision Effective Date: 10/17/2019. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35350&ver=60&Date=&DocID=L35350&bc=hAAAAAgAAAA&>
6. Cohen J, Safdi MA, Deal SE, et al. Quality Indicators for Esophagogastroduodenoscopy. *The American Journal of Gastroenterology* 101, 886-891 (April 2006). <http://www.nature.com/ajg/journal/v101/n4/full/ajg2006164a.html>
7. Corley D, Mehtani K, Quesenberry C, et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus–associated esophageal adenocarcinomas. *Gastroenterology*. 2013; 145(2):312-319. doi: 10.1053/j.gastro.2013.05.004. Epub 2013 May 11. [http://www.gastrojournal.org/article/S0016-5085\(13\)00715-4/pdf](http://www.gastrojournal.org/article/S0016-5085(13)00715-4/pdf)
8. Desai TK, Samala N. The incidence of esophageal adenocarcinoma among patients with nondysplastic Barrett's esophagus has been overestimated. (Letter). *Clin Gastroenterol Hepatol*, 2011 Apr; 9(4):363-364. <http://dx.doi.org/10.1016/j.cgh.2010.11.009>  
<https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/1-s2.0-S1542356510011894>
9. Enestvedt BK, Gralnek IM, Mattek N, et al. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. *Gastrointest Endosc*. 2008 Mar;67(3):422-429. doi: 10.1016/j.gie.2007.09.024. Epub 2008 Jan 18. <http://www.sciencedirect.com/science/article/pii/S0016510707026880#>
10. Freedman AS. Clinical Presentation and Management of Gastrointestinal lymphomas. Topic: 4721. Version 21.0. UpToDate. Updated: June 07,2017. Last reviewed: Dec. 2018, [https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas?search=management%20of%20gastrointestinal%20lymphomas&source=search\\_result&selectedTitle=2~150&usage\\_type=default&display\\_rank=2](https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-primary-gastrointestinal-lymphomas?search=management%20of%20gastrointestinal%20lymphomas&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2)

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH  
Last Review Date: 02/14/2020  
Effective Date: 04/01/2020

11. Hayes. Search & Summary. Preoperative Upper Endoscopy in Patients Undergoing Bariatric Surgery. February 11, 2016.
12. Hirano I, Richer J. American College of Gastroenterology (ACG) Practice Guidelines: Esophageal Reflux Testing., *Am J Gastroenterol* 2007 Mar;102:668–685., doi: 10.1111/j.1572-0241.2006.00936.x.  
<http://s3.gi.org/physicians/guidelines/EsophagealRefluxTesting.pdf>
13. Jasperson KJ, Burt R, APC-Associated Polyposis Conditions. *Gene Reviews*® [Internet]. Last updated: February 2, 2017 Available at:  
<http://www.ncbi.nlm.nih.gov/books/NBK1345/>
14. Kahrilas P, Shaheen N, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. *Gastroenterology*. 2008 Oct; 135(4): 1383-1391.e5. doi: 10.1053/j.gastro.2008.08.045.  
<http://www.sciencedirect.com/science/article/pii/S0016508508016065#>
15. Kaltenbach T, Sano Y, Freidland S, et al. American Gastroenterological Association (AGA) Institute Technology Assessment on Image-Enhanced Endoscopy. *Gastroenterology*. 2008 Jan; 134(1): 327-340. doi:10.1053/j.gastro.2007.10.062.  
[http://www.gastrojournal.org/article/S0016-5085\(07\)01942-7/pdf](http://www.gastrojournal.org/article/S0016-5085(07)01942-7/pdf)
16. Kocak E, Kilic F et. al. The usefulness of ulcer size and location in the differential diagnosis of benign and malignant gastric ulcer. *Wien Klin Wochenschr*. 2013 January 5; 125(1-2): 21-5. doi: 10.1007/s00508-012-0309-8.  
<http://link.springer.com/article/10.1007%2Fs00508-012-0309-8>
17. Katz P, Gerson L, Vela M. Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol*. 2013 Mar; 108:308-328; doi: 10.1038/ajg.2012.444; published online 19 February 2013. With corrigenda: 2013 Oct; 108:1672. [http://gi.org/wp-content/uploads/2013/10/ACG\\_Guideline\\_GERD\\_March\\_2013\\_plus\\_corrigendum.pdf](http://gi.org/wp-content/uploads/2013/10/ACG_Guideline_GERD_March_2013_plus_corrigendum.pdf)
18. Ladabaum U, Dinh V. Rate and yield of repeat upper endoscopy in patients with dyspepsia. *World J Gastroenterol*. 2010 May 28; 16(20): 2520–2525. doi:10.3748/wjg.v16.i20.2520.  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877181/pdf/WJG-16-2520.pdf>
19. National Digestive Diseases Information Clearinghouse, NIH Publication No. 14-4333, Reviewed by Michael Wallace, MD, Mayo Clinic. Page last updated: July 2017. <http://digestive.niddk.nih.gov/ddiseases/pubs/upperendoscopy/>
20. Pohl H, Robertson D, Welch HG. Repeated upper endoscopy in the Medicare population: a retrospective analysis. *Ann Intern Med*. 2014 Feb 4;160(3):154. doi: 10.7326/M13-0046. <http://annals.org/article.aspx?articleid=1819119>
21. Rosai J. Chapter 11 Gastrointestinal Tract. pp 585-813. *In*: Rosai & Ackerman's Surgical Pathology 10<sup>th</sup> Edition. Elsevier/Mosby: 2011
22. Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines

## PA.096.MH – Esophagogastroduodenoscopy

Policy Number: PA.096.MH

Last Review Date: 02/14/2020

Effective Date: 04/01/2020

committee of the American College of Physicians. Ann Intern Med. 2012;157(11):808-816. doi:10.7326/0003-4819-157-11-201212040-00008, <http://annals.org/article.aspx?articleID=1470281>

23. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010 Mar; 8(3):235-244; quiz e32. doi: 10.1016/j.cgh.2009.10.010. Epub 2010 Mar. <https://www.ncbi.nlm.nih.gov/pubmed/19850156>
24. Wang K, Sampliner R. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2015 Aug;103:788–797. Doi:10.1111/j.1572-0241.2008.01835x. <http://gi.org/wp-content/uploads/2015/11/ACG-2015-Barretts-Esophagus-Guideline.pdf>
25. American Society for Gastrointestinal Education . (ASGE). The role of endoscopy in the management of patients with peptic ulcer disease. Last Updated: 2010. [https://www.asge.org/docs/default-source/education/practice\\_guidelines/doc-the-role-of-endoscopy-in-the-management-of-patientswith-peptic-ulcer-disease.pdf?sfvrsn=6](https://www.asge.org/docs/default-source/education/practice_guidelines/doc-the-role-of-endoscopy-in-the-management-of-patientswith-peptic-ulcer-disease.pdf?sfvrsn=6)

### **Disclaimer:**

MedStar Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of MedStar Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

MedStar Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.